NL-OMON50777
已完成
不适用
ongkankernet implementation ctDNA Analysis - LICA
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Radboud Universitair Medisch Centrum
- 入组人数
- 250
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients with confirmed or suspected non\-small cell lung cancer
- •Signed informed consent
- •Adult (\>\= 18 years of age) and mentally competent
排除标准
- •Patients with a benign lesion
- •Patients with a metastasis of another primary cancer than lung cancer
结局指标
主要结局
未指定
相似试验
招募中
不适用
Implementation of up-front ctDNA analysis into lung cancer care and development of liquid biopsy-based decision support models - the Lungmarker2 studylung cancerlung carcinoma10029107NL-OMON53764Catharina-ziekenhuis800
已完成
不适用
TLA Technology: a new DNA diagnostic test to sequence genes that cause the disease and detect new mutations: proof of concept study voor patients with Rendu-Osler-Weber disease.Rendu-Osler-Weber hereditary hemorrhagic telangiectasia10007510NL-OMON39779Sint Antonius Ziekenhuis45
招募中
不适用
Dynamic liquid molecular profiling in anaplastic lymphoma kinase (ALK) Non-Small Cell Lung CancerAdvanced ALK+ NSCLCCancer - Lung - Non small cellACTRN12623000226606Peter MacCallum Cancer Centre55
进行中（未招募）
1 期
A trial using ctDNA mutation tracking to detect cancer cells in the blood of patients with triple negative breast cancer who have completed standard treatmentEarly stage triple negative breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000508-92-GBThe Institute of Cancer Research150
招募中
2 期
Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLCNL-OMON48173Antoni van Leeuwenhoek Ziekenhuis30